Firms May Lose Data Exclusivity Earlier Under Planned EU Adaptive Licensing Regime
This article was originally published in The Pink Sheet Daily
Executive Summary
Adaptive licensing is coming to Europe and, while it will be beneficial to patients, data exclusivity considerations may render it a double-edged sword to the innovative drug industry.